Patient dosing has begun in the global phase 3 ARCHER II trial to evaluate ANX007 (Annexon Biosciences), a novel therapy for treating geographic atrophy (GA). This pivotal trial, unique for its focus on visual protection as the primary endpoint, aims to confirm ANX007’s potential to preserve sight in patients with GA.

Recent data from the phase 2 ARCHER trial, presented at the American Society of Retina Specialists (ASRS) meeting, highlighted ANX007’s ability to protect visual acuity and retinal structure, demonstrating a significant reduction in vision loss and photoreceptor damage in patients with GA. If successful, ARCHER II could lead to the first FDA-approved treatment specifically designed to protect vision in GA patients, with topline results expected in the second half of 2026.

ANX007 has received Fast Track designation from the FDA and Priority Medicine (PRIME) status in the European Union.